Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043860 · ClinicalTrials.gov registry record · Phase 1
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02043860 is a Phase 1 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 3 participants.
The verdict
NCT02043860, a Phase 1 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
In this phase I trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI). This conventional 3+3 phase I trial will increase the dose of TMI until the maximum tolerated dose (MTD) is reached. Initial patients enrolled will receive the lowest possible dose of 3Gy. Maximum dose will be 12Gy.
Interventions
- DRUG Melphalan
- RADIATION Total Marrow Irradiation
- DRUG Filgrastim (G-CSF)
- PROCEDURE Autologous Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-01-10 |
| Est. Completion | 2016-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043860
The ClinicalTrials.gov registry entry for NCT02043860 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT02043860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043860 about?
NCT02043860 is a clinical study titled "Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma". In this phase I trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI). This conventional 3+3 phase I trial will increase the dose of TMI until ...
What is the current status of trial NCT02043860?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-01-10. Estimated completion is 2016-11-07.
What interventions are being tested in trial NCT02043860?
The interventions under investigation include: Melphalan (DRUG), Total Marrow Irradiation (RADIATION), Filgrastim (G-CSF) (DRUG), Autologous Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT02043860?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.